Role of autologous biological therapy in knee osteoarthritis. Intraosseous application of plasma rich in growth factors , improve of functional capacity and pain, compared to intraarticular application.

Fundacion para la investigacion biomedica HUPA0 个研究点开始时间: 2017年6月20日最近更新: 2017年10月2日

适应症

试验速览

暂无简介。

•Age between 40 and 75.
•Both genders.
•Moderate to several pain and symptoms according to the KOOS scale of more than 6 months of evolution.
•Grade III- IV knee osteoathritis according to radiological criteria for the classification of Kellgren and Lawrence.
•Patients with no response to other pharmacological treatments.
•Able to fulfill the schedule of visits of the trial.
•BMI less than 35.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 86
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 48

•Intraarticular infiltration with plasma rich in growth factors in the 12 months before the inclusion
•Intraarticular infiltration with hyaluronic acid in the 6 months before the inclusion.
•Angular alterations, higher than 15 degrees and unstable joint.
•Systemic or local infectious disease and polyarticular disease.
•Cancer under treatment or under follow-up.
•Immunosuppressive treatment or systemic autoimmune disease.
•Patient with hypertension or diabetes mellitus poorly controlled.
•Allergy to some study drugs or excipients.
•Patients on anticoagulants or antiplatelet therapy which cannot be reversed temporarily for infiltrations.
•Positive to sifilis, hepatitis B, hepatitis C or VIH+.
•Uncapable to understand or fulfill the questionnaries of the study.

发起方

Fundacion para la investigacion biomedica HUPA